Canaccord Genuity Maintains a Buy on Corcept Therapeutics (CORT), Retains a $137 PT

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the most promising future stocks according to Wall Street analysts. On August 14, analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Corcept Therapeutics Incorporated (NASDAQ:CORT), retaining the price target of $137.00.

Why Corcept Therapeutics Incorporated (CORT) Crashed On Monday

A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders.

The analyst based the rating on Corcept Therapeutics Incorporated’s (NASDAQ:CORT) strategic plans and promising developments, stating that the company made notable progress with its novel glucocorticoid modulator, relacorilant.

The modulator saw improvements in both regulatory and clinical arenas. Nash added that the FDA has also accepted an NDA submission for relacorilant for the treatment of Cushing’s syndrome, and a decision is anticipated by the end of 2025.

The analyst also stated that Corcept Therapeutics Incorporated (NASDAQ:CORT) submitted another NDA for relacorilant in combination with nab-paclitaxel for patients with platinum-resistant ovarian cancer, preparing for a potential launch by mid-2026.

Therefore, the potential of the expansion of relacorilant into oncology further supports the optimistic outlook for Corcept Therapeutics Incorporated (NASDAQ:CORT).

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biopharmaceutical company that develops and commercializes therapies that adjust the effects of cortisol, a hormone that regulates various bodily functions.

The company’s flagship product, Korlym, is FDA-approved for treating Cushing’s syndrome, a disorder caused by excessive cortisol production.

While we acknowledge the potential of CORT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CORT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.